Clinical Trials

Solid Tumor, Adult

NCT03905148 2026-01-07

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

91 enrolled

Solid Tumor, Adult

NCT05307874 2025-12-24

EVICTION-2

56 enrolled

Solid Tumor, Adult

NCT02220556 2025-08-08

CTC-CEC-ADN

Phase NA Completed

360 enrolled

Solid Tumor, Adult

NCT03410121 2025-08-05

PACPAC-EPOC

Phase NA Completed

361 enrolled

Solid Tumor, Adult

NCT03990233 2025-06-26

A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

100 enrolled

Solid Tumor, Adult

NCT05620472 2025-04-09

Molecular Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1

10 enrolled

Solid Tumor, Adult

NCT04597541 2025-03-10

A Study of AK112 for Advanced Solid Tumors

59 enrolled

Solid Tumor, Adult

NCT04105335 2025-03-06

TIMEPOINT

50 enrolled

Solid Tumor, Adult

NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

40 enrolled 16 charts

Solid Tumor, Adult

NCT03516123 2024-09-19

A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors

18 enrolled

Solid Tumor, Adult

NCT03523819 2024-09-19

A Study of CS1002 in Subjects with Advanced Solid Tumors

91 enrolled

Solid Tumor, Adult

NCT05117177 2024-09-19

New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer

57 enrolled

Solid Tumor, Adult

NCT04121442 2024-08-06

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

15 enrolled

Solid Tumor, Adult

NCT05054348 2024-06-04

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

91 enrolled

Solid Tumor, Adult

NCT05309187 2024-06-04

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

22 enrolled

Solid Tumor, Adult

NCT03728179 2024-02-20

RACIN

40 enrolled

Solid Tumor, Adult

NCT03274661 2023-10-19

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

Phase 2 Completed

52 enrolled 12 charts

Solid Tumor, Adult

NCT04683354 2023-02-13

Study of HL-085 in Patients With Advanced Solid Tumor Tumors

28 enrolled

Solid Tumor, Adult

NCT04428086 2022-07-26

A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.

19 enrolled

Solid Tumor, Adult

NCT03951116 2022-03-16

FCN-437c

22 enrolled

Solid Tumor, Adult

NCT03673020 2021-12-02

Phase 1a Study to Evaluate Immunogenicity of ASV®

3 enrolled

Solid Tumor, Adult

NCT03147378 2021-10-19

Food Effect Study of ModraDoc006 in Combination With Ritonavir

18 enrolled

Solid Tumor, Adult

NCT03360734 2021-07-12

GATTO

50 enrolled

Solid Tumor, Adult

NCT04515043 2021-06-01

EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)

6 enrolled

Solid Tumor, Adult

NCT03017521 2021-04-22

K-BASKET, TAS-117, PI3K/AKT Gene Aberration

Phase 2 Completed

13 enrolled

Solid Tumor, Adult

NCT03008018 2020-08-19

HDAC6i

20 enrolled

Solid Tumor, Adult

NCT03081819 2019-09-11

A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer

11 enrolled

Solid Tumor, Adult

NCT02717572 2019-04-05

18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR

19 enrolled

Solid Tumor, Adult

NCT03045003 2017-02-09

RESIL

Phase NA Completed

86 enrolled